Interactive Case: Choosing and Using CDK4/6 Inhibitors for Breast Cancer - Second-line Therapy

Program Type
Continuing Medical Education
Program Title
Interactive Case: Choosing and Using CDK4/6 Inhibitors for Breast Cancer - Second-line Therapy

 

The approvals of palbociclib and ribociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, provided advanced or metastatic hormone-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer patients with promising new treatment options. With a third CDK4/6 inhibitor, abemaciclib, approved in late September 2017, this class of therapy has become the new standard of care for HR+/HER2- breast cancer, which comprises the majority (approximately 75%) of all breast cancer cases. This interactive activity features expert faculty discussing practical aspects of using this class of agents as second-line therapy in HR+/HER2- advanced or metastatic breast cancer.